Nanobiotix Reports 2026 H1 Earnings, Highlights Nanomedicine R&D Momentum and FDA/EMA Push
Nanobiotix SA reports a first‑half 2026 update: negative earnings but growing revenue from partnerships, advancing its NBTXR3 NanoXray® platform, and positioning for future nanomedicine growth.
3 minutes to read